Prostate Cancer Coverage from Every Angle

Felix Y. Feng, MD, on Predicting the Efficacy of Apalutamide in Patients With Castration-Resistant Prostate Cancer

Posted: Monday, February 22, 2021

Felix Y. Feng, MD, of the University of California, San Francisco, talks about why findings from the phase III SPARTAN trial, along with his study findings, point toward the clinical use of molecular determinants to help predict whether apalutamide and other androgen-signaling inhibitors may benefit patients with nonmetastatic castration-resistant prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.